Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the <scp>SUPER2</scp> trial: A post‐hoc analysis for comprehensive evaluation
Efsubaglutide Alfa 1 mg provided clinically meaningful glucose lowering with good tolerability but without significant weight loss. These results support a lower-dose strategy for elderly or frail patients, those with low BMI, or individuals sensitive to gastrointestinal effects, and as a possible lead-in step before escalation. Confirmatory trials are warranted to establish long-term outcomes.
Authors
- Qinghua Wang (ORCID: https://orcid.org/0000-0002-6478-0988)
- Weiping Jia (ORCID: https://orcid.org/0000-0002-6244-2168)
- Yuqian Bao (ORCID: https://orcid.org/0000-0002-4754-3470)
- Fan Jiang (ORCID: https://orcid.org/0000-0002-1145-1304)
- Yiming Li (ORCID: https://orcid.org/0000-0002-7324-9435)
- Yulong Xu (ORCID: https://orcid.org/0000-0002-5131-1242)
Institutions
- Fudan University (CN)
- Buchang Pharma (China) (CN)
- Shanghai Sixth People's Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1111/dom.70112
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29